Safety and Effectiveness of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia (Sphere VT)

Sphere VT is a prospective, multi-center, single-arm, unblinded pivotal clinical study. Adult subjects with recurrent, sustained, monomorphic ventricular tachycardia (MMVT) due to prior myocardial infarction (MI) will be enrolled and treated with the Sphere-9 Catheter and Affera Ablation System.

NCT Number	NCT07585968
Lead Sponsor	Medtronic Cardiac Ablation Solutions
Conditions	Ventricular Tachycardia
Enrollment	260 participants
Start Date	2026-06
Primary Completion	2028-03 (estimated)
Study Completion	2028-09 (estimated)
Updated on ClinicalTrials.gov	2026-07-30